|
1
|
Bordonaro M and Lazarova DL: CREB-binding
protein, p300, butyrate, and Wnt signaling in colorectal cancer.
Word J Gastroenterol. 21:8238–8248. 2015. View Article : Google Scholar
|
|
2
|
Wang J, Wang X, Lin S, Chen C, Wang C, Ma
Q and Jiang B: Identification of kininogen-1 as a serum biomarker
for the early detection of advanced colorectal adenoma and
colorectal cancer. PLoS One. 8:e705192013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Okada K, Fujiwara Y, Nakamura Y, Takiguchi
S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Takahashi T, Mori
M and Doki Y: Oncofetal protein, IMP3, a potential marker for
prediction of postoperative peritoneal dissemination in gastric
adenocarcinoma. J Surg Oncol. 105:780–785. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li D, Yan D, Tang H, Zhou C, Fan J, Li S,
Wang X, Xia J, Huang F, Qiu G and Peng Z: IMP3 is a novel
prognostic marker that correlates with colon cancer progression and
pathogenesis. Ann Surg Oncol. 16:3499–3506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Perak Beljan R, Durdov MG, Capkun V,
Ivcevic V, Pavlovic A, Soljic V and Peric M: IMP3 can predict
aggressive behaviour of lung adenocarcinoma. Diagn Pathol.
7:1652012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yantiss RK, Woda BA, Fanger GR, Kalos M,
Whalen GF, Tada H, Andersen DK, Rock KL and Dresser K: KOC (K
honlology domain containing protein overexpressed in cancer): A
novel molecular maker that distinguishes between benign and
malignant lesions of the pancreas. Am J Surg Pathol. 29:188–195.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kumara Shantha H, Kirchoff D, Caballero
OL, Su T, Ahmed A, Herath SA, Njoh L, Cekic V, Simpson AJ,
Cordon-Cardo C and Whelan RL: Expression of the cancer testis
antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a
specific immunotherapy target. Oncoscience. 2:607–614. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Riveiro-Falkenbach E and Soengas MS:
Control of tumorigenesis and chenoresistance by the DEK oncogene.
Clin Cancer Res. 16:2932–2938. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang L, Xu Y, Cai G, Guan Z and Cai S:
Downregulation of S100A4 expression by RNA interference suppresses
cell growth and invasion in human colorectal cancer cells. Oncol
Rep. 27:917–922. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Khodadoust MS, Verhaegen M, Kappes F,
Riveiro-Falkenbach E, Cigudosa JC, Kim DS, Chinnaiyan AM, Markovitz
DM and Soengas MS: Melanoma proliferation and chemoresistance
controlled by the DEK oncogene. Cancer Res. 69:6405–6413. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oyarzo MP, Lin P, Glassman A, Bueso-Ramos
CE, Luthra R and Medeiros LJ: Acute myeloid leukemia with
t(6;9)(p23;q34) is associated with dysplasia and a high frequency
of flt3 gene mutations. Am J Clin Pathol. 122:348–358. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lederer M, Bley N, Schleifer C and
Hüttelmaier S: The role of the oncofetal IGF2 mRNA-binding protein
3 (IGF2BP3) in cancer. Semin Cancer Biol. 29:3–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bell JL, Wächter K, Mühleck B, Pazaitis N,
Köhn M, Lederer M and Hüttelmaier S: Insulin-like growth factor 2
mRNA-binding proteins (IGF2BPs): Post-transcriptional drivers of
cancer progression? Cell Mol Life Sci. 70:2657–2675. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Park JY, Choe M, Kang Y and Lee SS: IMP3,
a promising prognostic marker in clear cell renal cell carcinoma.
Korean J Pathol. 48:108–116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang L, Li HG, Xia ZS, Lü J and Peng TS:
IMP3 is a novel biomarker to predict metastasis and prognosis of
gastric adenocarcinoma: A retrospective study. Chin Med J (Engl).
123:3554–3558. 2010.PubMed/NCBI
|
|
16
|
Lin L, Piao J, Ma Y, Jin T, Quan C, Kong
J, Li Y and Lin Z: Mechanisms underlying cancer growth and
apoptosis by DEK overexpression in colorcetal cancer. PLoS One.
9:e1112602014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y,
Li J and Lin Z: DEK over expression as an independent biomarker for
poor prognosis in colorectal cancer. BMC Cancer. 13:3662013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu K, Feng T, Liu J, Zhong M and Zhang S:
Silencing of the DEK gene induces apoptosis and senescence in CaSki
cervical carcinoma cells via the up-regulation of NF-κB p65. Biosci
Rep. 32:323–332. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cavallaro U and Christofori G: Cell
adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev
Cancer. 4:118–132. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oliveras-Ferraros C, Corominas-Faja B,
Cufí S, Vazquez-Martin A, Martin-Castillo B, Iglesias JM,
López-Bonet E, Martin ÁG and Menendez JA: Epithelial-to-mesenchymal
transition (EMT) confers primary resistance to trastuzumab
(Herceptin). Cell Cycle. 11:4020–4032. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sarkar FH, Li Y, Wang Z and Kong D:
Pancreatic cancer stem cells and EMT in drug resistance and
metastasis. Minerva Chir. 64:489–500. 2009.PubMed/NCBI
|
|
22
|
Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL,
Wang TH and Hsu HC: RNA-binding protein insulin-like growth factor
II mRNA-binding protein 3 expression promotes tumor invasion and
predicts early recurrence and poor prognosis in hepatocellular
carcinoma. Hepatology. 48:1118–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen C, Wang FH, An X, Luo HY, Wang ZQ,
Liang Y, Zhang L and Li YH: Triplet combination with paclitaxel,
cisplatin and 5-FU is effective in metastatic and/or recurrent
nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 71:371–378.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wise-Draper TM, Allen HV, Jones EE, Habash
KB, Matsuo H and Wells SI: Apoptosis inhibition by the human DEK
oncoprotein involves interfer-ence with p53 functions. Mol Cell
Biol. 26:7506–7519. 2006. View Article : Google Scholar : PubMed/NCBI
|
